Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Novartis
Cipla
Accenture
Teva
McKesson
Chubb
Harvard Business School
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,881,726

« Back to Dashboard

Which drugs does patent 6,881,726 protect, and when does it expire?

Patent 6,881,726 protects METROGEL and is included in one NDA.

This patent has twenty-six patent family members in nineteen countries.
Summary for Patent: 6,881,726
Title: Aqueous compositions containing metronidazole
Abstract:An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is a compound other than a cyclodextrin. Methods of manufacture and therapeutic use of the solution are disclosed.
Inventor(s): Chang; Yunik (Sonoma, CA), Dow; Gordon J. (Santa Rosa, CA)
Assignee: Dow Pharmaceutical Sciences (Petaluma, CA)
Application Number:10/033,835
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Device;

Drugs Protected by US Patent 6,881,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp METROGEL metronidazole GEL;TOPICAL 021789-001 Jun 30, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,881,726

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,348,317 Aqueous compositions containing metronidazole ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,881,726

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2413501 ➤ Subscribe
Russian Federation 2006116252 ➤ Subscribe
Russian Federation 2284810 ➤ Subscribe
Russian Federation 2004122696 ➤ Subscribe
Portugal 1467744 ➤ Subscribe
Mexico PA04006210 ➤ Subscribe
South Korea 100718858 ➤ Subscribe
South Korea 20040075911 ➤ Subscribe
Japan 4611632 ➤ Subscribe
Japan 2005532990 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Merck
Harvard Business School
Deloitte
Fish and Richardson
McKinsey
Colorcon
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot